(DSMZ) Announce Collaboration on Identification of Microorganisms

[Guest guest]

February 21, 2006 07:00 AM US Eastern Timezone

Bruker Daltonics and German Collection of Microorganisms and Cell

Cultures (DSMZ) Announce Collaboration on Identification of

Microorganisms

by MALDI-TOF Mass Spectrometry

BIOWIRE2K

San Francisco,CA

http://home.businesswire.com/portal/site/google/index.jsp?

ndmViewId=news_view & newsId=20060221005593 & newsLang=en

Smart Multimedia Gallery

Dr. Erko Stackebrandt (Photo: Business Wire) BREMEN and

BRAUNSCHWEIG, Germany--(BUSINESS WIRE)--Feb. 21, 2006--Bruker

Daltonik GmbH and the German Collection of Microorganisms and Cell

Cultures (DSMZ) today announced a collaboration for the

identification and classification of microorganisms from peptide and

protein profiles measured by MALDI-TOF mass spectrometry. The DSMZ

uses Bruker Daltonik's novel CLINPROT BioTyper system to

generate protein profiles and to perform the required advanced data

analysis.

The DSMZ is the German National Resource Centre for Biological

Material, and currently stores and maintains approximately 14,000

cultures, representing 6,900 species from different types of

microorganisms, including archaea, bacteria, yeasts and fungi. In

the course of the planned collaboration, a comprehensive database

will be generated that will include species and strains for many

different application areas such as microbiological classification,

clinical and diagnostic infectious disease research, as well as

environmental analysis, food safety and water quality. The DSMZ will

use the CLINPROT BioTyper for its internal quality control of

strains, as well as for its on-going phylogenetic research in

various microorganisms.

The DSMZ adopted the CLINPROT BioTyper technology for microorganism

characterization due to the ability of MALDI-TOF mass spectrometry

to identify large numbers of samples originating from complex

mixtures of microorganisms, unequivocally and without the need for

expert training. The convenient and cost-effective CLINPROT BioTyper

sample preparation outperforms other approaches. Moreover, the

CLINPROT BioTyper system includes an easy-to-operate bench-top MALDI-

TOF with a small footprint that is well suited for operation in

biological laboratories that are not mass spectrometry core

facilities.

Prof. Dr. Erko Stackebrandt, Managing Director of DSMZ, pointed

out: " There was an urgent need for a next- generation technique for

the fast, convenient and cost-effective identification of microbial

strains. Bruker Daltonik's CLINPROT BioTyper is well suited for this

purpose, as it fulfills these requirements. It has proven to be very

robust and reproducible. "

Dr. Wolfgang Pusch, Director of Clinical Proteomics and Biomarker

Analysis, commented: " We are very pleased to have the DSMZ with

their extraordinary expertise in microbiology as a strategic

partner. This cooperation is a major step towards our goal of not

only applying mass spectrometry in expert core facilities, but also

making it available as a robust tool in routine biological analysis.

The dual capabilities of our ClinProt MALDI-TOF systems for

microorganism identification, as well as for tissue and body-fluid

protein biomarker discovery, should be attractive for many clinical

diagnostics research laboratories. "

The CLINPROT BioTyper system will be introduced internationally at

the Bruker Daltonics Pittcon booth #3155 in Orlando, Florida on

March 13-16, 2006.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica,

Massachusetts, is the publicly traded parent company of Bruker

Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer

and provider of life science, materials research and industrial X-

ray analysis tools. Bruker Daltonics is a leading developer and

provider of innovative life science tools based on mass

spectrometry. Bruker Daltonics also offers a broad line of nuclear,

biological and chemical (NBC) detection products for defense and

homeland security. For more information, please visit www.bruker-

biosciences.com

ABOUT DSMZ

The DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen

GmbH (German Collection of Microorganisms and Cell Cultures) is the

most comprehensive biological resource center in Europe. With more

than 14,000 microorganisms, 900 plant viruses, 550 human and animal

cell lines, 500 plant cell cultures and more than 6,300 cultures

deposited, the DSMZ has demonstrated its commitment to serve science

for decades. Since 2004, the DSMZ is certified by DIN EN ISO 9001-

2000. The DSMZ mission is 1) to collect, maintain and store

biological material of relevance for applied biology, biotechnology,

microbiology, teaching and other areas of research and general

application, and 2) to perform collection-related research on these

resources. The DSMZ is an independent, non-profit organisation. For

more information, please visit www.dsmz.de

CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

Any statements contained in this press release that do not describe

historical facts may constitute forward-looking statements as that

term is defined in the Private Securities Litigation Reform Act of

1995. Any forward-looking statements contained herein are based on

current expectations, but are subject to a number of risks and

uncertainties. The factors that could cause actual future results to

differ materially from current expectations include, but are not

limited to, risks and uncertainties relating to the Company's

reorganization strategies, integration risks, failure of conditions,

technological approaches, product development, market acceptance,

cost and pricing of the Company's products, changes in governmental

regulations, capital spending and government funding policies, FDA

and other regulatory approvals to the extent applicable,

competition, the intellectual property of others, patent protection

and litigation. These and other factors are identified and described

in more detail in our filings with the SEC, including, without

limitation, our respective annual reports on Form 10-K for the year

ended December 31, 2004, our most recent quarterly reports on Form

10-Q, and our current reports on Form 8-K. We disclaim any intent or

obligation to update these forward-looking statements.